Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-61,985
Closed -$12.1M 85
2018
Q4
$12.1M Sell
61,985
-450
-0.7% -$87.8K 2.61% 15
2018
Q3
$12.9M Sell
62,435
-1,600
-2% -$315K 2.27% 15
2018
Q2
$11.8M Hold
64,035
2.21% 15
2018
Q1
$10.9M Sell
64,035
-1,460
-2% -$268K 2.06% 15
2017
Q4
$11.4M Buy
65,495
+60
+0.1% +$10.6K 2.15% 15
2017
Q3
$12.2M Buy
65,435
+50
+0.1% +$8.86K 2.49% 15
2017
Q2
$11.3M Buy
65,385
+400
+0.6% +$65.1K 2.38% 15
2017
Q1
$10.7M Buy
64,985
+2,900
+5% +$482K 2.4% 13
2016
Q4
$9.08M Sell
62,085
-600
-1% -$90.3K 2.24% 12
2016
Q3
$10.5M Sell
62,685
-2,100
-3% -$355K 2.58% 12
2016
Q2
$9.86M Sell
64,785
-18
-0% -$2.8K 2.5% 12
2016
Q1
$9.72M Buy
64,803
+225
+0.3% +$33.4K 2.53% 13
2015
Q4
$10.5M Buy
64,578
+50
+0.1% +$7.86K 2.55% 12
2015
Q3
$8.93M Buy
64,528
+3,350
+5% +$528K 2.14% 16
2015
Q2
$9.39M Buy
61,178
+11,650
+24% +$1.87M 1.95% 19
2015
Q1
$7.92M Buy
49,528
+28,690
+138% +$4.52M 1.66% 21
2014
Q4
$3.32M Hold
20,838
0.73% 31
2014
Q3
$2.93M Buy
20,838
+1,375
+7% +$180K 0.65% 32
2014
Q2
$2.3M Buy
19,463
+17,490
+886% +$2.02M 0.5% 36
2014
Q1
$243K Hold
1,973
0.05% 84
2013
Q4
$225K Buy
1,973
+75
+4% +$8.53K 0.05% 87
2013
Q3
$212K Buy
+1,898
New +$206K 0.05% 92

Other funds holding AMGN

Jay A. Fishman Ltd's AMGN Position: Q1 2019 in Review

Jay A. Fishman Ltd sold out of Amgen (AMGN) in Q1 2019, closing a stake of 61,985 shares — an estimated $12.1M sold.

Jay A. Fishman Ltd first reported a position in AMGN in Q3 2013 and held it in 22 quarters. The position peaked at $12.9M in Q3 2018. 1,886 funds tracked by Wall St. Rank hold AMGN as of Q1 2019.

  • Jay A. Fishman Ltd reported no remaining Amgen position as of Q1 2019 after selling out during the quarter.
  • Jay A. Fishman Ltd sold 61,985 Amgen shares in Q1 2019, an estimated $12.1M.
  • Jay A. Fishman Ltd first reported a position in Amgen in Q3 2013 and held it in 22 quarters.
  • Jay A. Fishman Ltd's Amgen position peaked at $12.9M in Q3 2018.
  • 1,886 funds tracked by Wall St. Rank held Amgen as of Q1 2019.

Based on Jay A. Fishman Ltd's 13F filing for Q1 2019, filed 1 May 2019.